Laurus Labs has invested Rs 107.80 crore and acquired 10.78 crore equity shares of KRKA Pharma (KRKA) at face value of Rs 10 each by way of rights issue. KRKA is a joint venture company between KRKA d.d., Novo mesto, Slovenia and the company. Post this investment, the total holding of the company in KRKA is 262,150,000 equity shares of Rs 10 each and the percentage of shareholding by the company shall remain same at 49%.
Earlier, the Board of Directors of the company at their meeting held on April 30, 2026, had approved the said investment.
Laurus Labs is engaged in offering a broad and integrated portfolio of API including intermediates, Generic FDF and Contract Research services to cater to the needs of the global pharmaceutical industry and to develop novel enzyme solutions for Industrial Biotechnology and Animal Origin Free recombinant proteins and enzymes for biopharma.
